Search hospitals > California > Orange
UC Irvine Health/Chao Family Comprehensive Cancer Center
Claim this profileOrange, California 92868
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Adenocarcinoma
Conducts research for Leukemia
519 reported clinical trials
47 medical researchers
Summary
UC Irvine Health/Chao Family Comprehensive Cancer Center is a medical facility located in Orange, California. This center is recognized for care of Cancer, Breast Cancer, Ovarian Cancer, Adenocarcinoma, Leukemia and other specialties. UC Irvine Health/Chao Family Comprehensive Cancer Center is involved with conducting 519 clinical trials across 499 conditions. There are 47 research doctors associated with this hospital, such as David Hong, MD, Deepa Jeyakumar, Farshid Dayyani, and Jennifer B. Valerin.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
HER2 positive
Top PIs
David Hong, MDM D Anderson Cancer Center3 years of reported clinical research
Expert in Tumors
Expert in Solid Tumors
23 reported clinical trials
47 drugs studied
Deepa JeyakumarUC Irvine Health/Chao Family Comprehensive Cancer Center3 years of reported clinical research
Expert in Leukemia
Expert in Acute Myeloid Leukemia
20 reported clinical trials
47 drugs studied
Farshid DayyaniUC Irvine Health/Chao Family Comprehensive Cancer Center4 years of reported clinical research
Expert in Adenocarcinoma
Studies Cancer
21 reported clinical trials
48 drugs studied
Jennifer B. ValerinUC Irvine Health/Chao Family Comprehensive Cancer Center4 years of reported clinical research
Studies Pancreatic Cancer
Studies Cancer
17 reported clinical trials
32 drugs studied
Clinical Trials running at UC Irvine Health/Chao Family Comprehensive Cancer Center
Breast Cancer
Cancer
Diffuse Large B-Cell Lymphoma
Colorectal Cancer
Pancreatic Cancer
Lymphoma
Prostate Cancer
B-Cell Lymphoma
Tumors
Ovarian Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UC Irvine Health/Chao Family Comprehensive Cancer Center?
UC Irvine Health/Chao Family Comprehensive Cancer Center is a medical facility located in Orange, California. This center is recognized for care of Cancer, Breast Cancer, Ovarian Cancer, Adenocarcinoma, Leukemia and other specialties. UC Irvine Health/Chao Family Comprehensive Cancer Center is involved with conducting 519 clinical trials across 499 conditions. There are 47 research doctors associated with this hospital, such as David Hong, MD, Deepa Jeyakumar, Farshid Dayyani, and Jennifer B. Valerin.
Where is UC Irvine Health/Chao Family Comprehensive Cancer Center located?
**UC Irvine Health/Chao Family Comprehensive Cancer Center**
- **Address:** 101 The City Drive South, Building 23, Orange, CA 92868.
- **Location:** Situated in the city of Orange, California, and easily accessible via the I-5 freeway.
Who should I call to ask about financial aid or insurance network?
**UC Irvine Health/Chao Family Comprehensive Cancer Center Contact Information:**
- **Financial Assistance:**
- Website: [Financial Assistance Information](https://www.ucihealth.org/patients-visitors/financial-assistance)
- Phone: 833-353-7700 (Monday-Friday, 8:30 a.m. - 4 p.m.)
- **Insurance Inquiries:**
- Website: [Insurance Information](https://www.ucihealth.org/patients-visitors/insurance)
- For specific questions, contact the physician group listed on the insurance page.
- **General Information:**
- Main Website: [UCI Chao Family Comprehensive Cancer Center](https://cancer.uci.edu)
What insurance does UC Irvine Health/Chao Family Comprehensive Cancer Center accept?
UC Irvine Health/Chao Family Comprehensive Cancer Center accepts a wide range of insurance plans. This includes PPOs such as Aetna, Anthem Blue Cross, and United Healthcare; HMOs including Anthem Blue Cross, Blue Shield, and United Healthcare HMO; and Behavioral Health plans like Anthem Behavioral Health and Optum Behavioral Health. They also accept Covered California plans, Medicare, and Medi-Cal.
What awards or recognition has UC Irvine Health/Chao Family Comprehensive Cancer Center received?
The UC Irvine Health/Chao Family Comprehensive Cancer Center, located in Orange, California, is recognized as a top cancer center by the National Cancer Institute (NCI), holding the prestigious "comprehensive" designation. It is one of only 53 NCI-designated comprehensive cancer centers in the U.S. and the sole center in Orange County. The center excels in scientific discovery, clinical innovation, and efforts to reduce cancer incidence and mortality, especially in underserved communities.